Semaglutide supply will remain unstable until end of 2023, warns TGA
Risk of further supply disruptions makes it difficult to start new patients on the drug just yet, says Dr Gary Deed.
Semaglutide could remain in short supply until the end of the year despite increased stock, the TGA has warned, amid concerns a rise in off-label prescribing for weight loss could spark another shortage.
The regulator’s shortage listing for the GLP-1 receptor agonist was due to expire on 30 June, but on Wednesday this was extended until 31 December following advice from the drug’s sponsor.
